These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 34149730)

  • 1. The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer.
    Ren S; Xiong X; You H; Shen J; Zhou P
    Front Immunol; 2021; 12():689132. PubMed ID: 34149730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Research Progress of Anti-angiogenic Agents Combined with Immunotherapy 
in Patients with Advanced Non-small Cell Lung Cancer].
    Wang J; Peng W; Jiang M; Wu L
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):196-203. PubMed ID: 33819970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
    Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
    Front Immunol; 2020; 11():1956. PubMed ID: 32983126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
    Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
    Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer.
    Choi SH; Yoo SS; Lee SY; Park JY
    Arch Pharm Res; 2022 Apr; 45(4):263-279. PubMed ID: 35449345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
    Georganaki M; van Hooren L; Dimberg A
    Front Immunol; 2018; 9():3081. PubMed ID: 30627131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality.
    Pircher A; Wolf D; Heidenreich A; Hilbe W; Pichler R; Heidegger I
    Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29088109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Review on the Combination Strategy of Anti-angiogenic Agents 
and Other Anti-tumor Agents in Advanced Non-small Cell Lung Cancer].
    Xu Z; Li J
    Zhongguo Fei Ai Za Zhi; 2021 May; 24(5):357-364. PubMed ID: 34034460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.
    Perdrizet K; Leighl NB
    Curr Treat Options Oncol; 2019 Feb; 20(3):21. PubMed ID: 30778772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study.
    Yao J; Wang Z; Sheng J; Wang H; You L; Zhu X; Pan H; Han W
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107033. PubMed ID: 33039958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice.
    Zouein J; Haddad FG; Eid R; Kourie HR
    Immunotherapy; 2022 Feb; 14(2):155-167. PubMed ID: 34865502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?
    Popat S; Grohé C; Corral J; Reck M; Novello S; Gottfried M; Radonjic D; Kaiser R
    Lung Cancer; 2020 Jun; 144():76-84. PubMed ID: 32387684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Story of Angiogenesis Inhibitors in Non-small-cell Lung Cancer: The Past, Present, and Future.
    Shukla NA; Yan MN; Hanna N
    Clin Lung Cancer; 2020 Jul; 21(4):308-313. PubMed ID: 32291211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging therapeutic agents for advanced non-small cell lung cancer.
    Chen R; Manochakian R; James L; Azzouqa AG; Shi H; Zhang Y; Zhao Y; Zhou K; Lou Y
    J Hematol Oncol; 2020 May; 13(1):58. PubMed ID: 32448366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
    Chen Y; Gao M; Huang Z; Yu J; Meng X
    J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy.
    Lefebvre C; Martin E; Hendriks LEL; Veillon R; Puisset F; Mezquita L; Ferrara R; Sabatier M; Filleron T; Dingemans AC; Besse B; Raherisson C; Mazières J
    Respir Med Res; 2020 Nov; 78():100788. PubMed ID: 32980653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.
    Qiang H; Chang Q; Xu J; Qian J; Zhang Y; Lei Y; Han B; Chu T
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):631-645. PubMed ID: 32065262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8
    Liu Y; Zhang T; Zhang L; Zhao C; Zhang Z; Wang Z; Gu M; Li W; Li B
    Immunotherapy; 2022 Jun; 14(9):695-708. PubMed ID: 35574588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.